Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ETBX-051 + ETBX-061 + ETBX-071|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ETBX-051||ETBX-051 is a virally based vaccine that infects cells and induces expression of the brachyury protein protein, which may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against brachyury expressing tumor cells (NCI Drug Dictionary).|
|ETBX-061||ETBX-061 is a virally based vaccine that infects cells and causes expression of the Muc1 protein, which may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against Muc1 expressing tumor cells (NCI Drug Dictionary).|
|ETBX-071||ETBX 071|ETBX071|Adenoviral PSA Vaccine ETBX-071||ETBX-071 is an engineered adenovirus vaccine that expresses human prostate specific antigen (PSA) in infected cells, which potentially activates cytotoxic T-lymphocytes against tumor cells expressing PSA (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03481816||Phase I||ETBX-051 + ETBX-061 + ETBX-071||Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines||Active, not recruiting|